![[Graphic News] Seoul ranks 8th among global startup hubs](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F07%2F06%2Fnews-p.v1.20250706.e92e8fc8aa9642a3bb29d70ad465d85d_T1.gif&w=3840&q=100)
[Graphic News] Seoul ranks 8th among global startup hubs
The 2025 report analyzed the startup environments of 300 cities worldwide, and Seoul remained in the top 10 for the second consecutive year, moving up from 9th in 2024. The city first entered the top 10 in 2022 but dropped to 12th in 2023 due to challenges such as weak investment flows, high inflation and rising interest rates.
Topping the list were Silicon Valley (1st), New York (2nd) and London (3rd) — long-standing global leaders known for their deep talent pools, strong funding ecosystems and robust innovation infrastructure.
The Seoul city government highlighted that this year's all-time high ranking is especially meaningful as it places the city ahead of other major Asian startup hubs like Singapore (9th) and Tokyo (11th).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management, Company K Partners, GS Ventures, and Dayli Partners, reaffirmed their commitment. They were joined by ten new investors: LB Investment, TS Investment, Shinhan Venture Investment, S&S Investment, Hana Ventures, Maple Investment Partners, A Ventures, IMM Investment, Schmidt, and Industrial Bank of Korea. The proceeds will be used to accelerate the development of GAIA-based Alzheimer's Disease therapeutics, expand its target indications to various immune disorders, and broaden its pipeline of potential blockbuster drug candidates. The company is actively pursuing early-stage collaborations with global pharmaceutical companies and research institutions to add value to internal programs. "In the evolving landscape of new drug development where the limitations of existing medications are continually being overcome, Illimis' differentiated platform technology is expected to emerge as a next-generation treatment option for neuro-immune diseases with high unmet medical needs," said Yohan Kim, Senior Managing Director at DSC Investment, who led this investment round and has also been appointed to the board of directors. Jiwoong Chun, Managing Director at Woori Venture Partners and an active board member and investor since the company's inception, added, "Illimis is a prime example of a smart Korean biotech unlocking global markets with proprietary innovation and capital efficiency." Illimis has recently been selected for the '2025 Global Joint Research to Defeat Dementia' led by the Ministry of Health and Welfare and the Korean Dementia Research Center, securing KRW 2.2 million ($1.6 million) in funding over three years, further validating its technological capabilities. This initiative aims to develop Alzheimer's therapeutics through global joint research leveraging the GAIA platform, positioning Illimis at the center of international collaboration. Furthermore, in October 2024, Illimis partnered with Eli Lilly and Company (Lilly)'s Catalyze360-ExploR&D, a core pillar of external innovation at Lilly dedicated to deploying world-leading research and development capabilities and scientific know-how to accelerate partner science. Under this research collaboration, Illimis and Lilly have been cooperating to advance the platform construct for applications in neurodegenerative diseases. Illimis has also strengthened its global pharma collaborations by winning the 2023 BMS Innovation Square Challenge and joining Johnson & Johnson's global incubator network as a member company of JLABS Singapore in 2024. To further enhance its drug development competitiveness, Illimis Therapeutics operates a Scientific Advisory Board (SAB). The SAB includes Dr. Greg Lemke, Emeritus Professor at the Salk Institute and a world-renowned expert in TAM Biology, and Dr. Morgan Sheng, a leading neuroscientist at the Broad Institute who previously served as Vice President of Neuroscience at Genentech. These experts provide strategic guidance across the entire R&D lifecycle, including pipeline development, candidate discovery, clinical trial design, etc., and play a pivotal role in strengthening Illimis Therapeutics' global partnerships. "This investment, government grants, and partnership with Lilly will enable us to accelerate our efforts to conquer diseases with high unmet clinical needs based on a comprehensive understanding of TAM biology and establish global leadership in TAM biology," said Sanghoon Park, CEO of Illimis Therapeutics. "We will continue to focus on innovative new drug development centered around the GAIA platform and provide tangible treatment options to patients worldwide through early R&D collaboration models." About Illimis Therapeutics Illimis Therapeutics is a pioneering biotechnology company at the forefront of developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. The company's core strength lies in its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This cutting-edge platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved in regulating inflammation and immune responses. The company's lead pipeline, ILM01 for the treatment of Alzheimer's Disease, is entering into the preclinical stage in the second half of 2025 and expecting to submit an IND by the end of 2027. For more information, visit
Korea Herald
2 hours ago
- Korea Herald
Arrest warrants sought for construction firm officials in case allegedly involving ex-first lady
The special counsel team investigating allegations involving former first lady Kim Keon Hee filed for warrants Monday to arrest four construction company officials over a stock manipulation case allegedly linked to her. The investigation team, led by special counsel Min Joong-ki, said it filed the warrants against Lee Il-jun and Cho Sung-wok, current and former chairman of Sambu Construction Co., respectively, along with a former vice chairman and a former CEO, on charges of violating the Capital Markets Act. It marks the first time arrest warrants have been sought by the special counsel team since it launched its investigation into allegations involving Kim earlier this month. The four executives are accused of allegedly duping investors into buying the firm's shares in 2023 on false information that it would take part in reconstruction projects in war-torn Ukraine, then selling off their shares at inflated prices to pocket massive illegal profits. The former first lady is alleged to have played a role in the scheme. Also on Monday, the special counsel team summoned the founder of Kakao Corp. and executives of several other companies for questioning over an investment scandal linked to one of Kim's aides. Kakao founder Kim Beom-su; vice chairman of HS Hyosung Corp. Jo Hyeong-sang; former president of the Korea Securities Finance Corp. Yoon Chang-ho; and former Daou Kiwoom Group Chairman Kim Ik-rae were told to appear for questioning at 10 a.m. Thursday. The scandal centers on allegations that a man surnamed Kim, who served as a "butler" for the former first lady's family, had reportedly received 18 billion won (US$13 million) in illegal investments from several companies, including Kakao Mobility Corp., for his rental car company, IMS, in 2023. The special counsel suspects that the funds invested in IMS may have been funneled to the former first lady in the form of slush funds. The executives were summoned as witnesses in the case, though their status could change to suspects depending on the outcome of the probe, officials said. "We will begin questionings of top decision makers of the companies (involved) ... this week to swiftly find the truth behind the so-called 'butler gate' and prevent the destroying of evidence," assistant special counsel Oh Jung-hee said in a regular press briefing.
Korea Herald
3 hours ago
- Korea Herald
Special counsel summons Kakao founder, others for questioning in probe into ex-first lady
The special counsel team investigating allegations involving former first lady Kim Keon Hee on Monday summoned the founder of Kakao Corp. and executives of several other companies for questionings over an investment scandal linked to one of Kim's aides. The investigation team, led by special counsel Min Joong-ki, said it summoned Kakao founder Kim Beom-su; vice chairman of HS Hyosung Corp. Jo Hyeong-sang; former president of the Korea Securities Finance Corp. Yoon Chang-ho; and former Daou Kiwoom Group Chairman Kim Ik-rae to appear for questioning at 10 a.m. Thursday. The scandal centers on allegations that a man surnamed Kim, who served as a "butler" for the former first lady's family, had reportedly received 18 billion won (US$13 million) in illegal investments from several companies, including Kakao Mobility Corp., for his rental car company, IMS, in 2023. The special counsel suspects that the funds invested in IMS may have been funneled to the former first lady in the form of slush funds. The executives were summoned as witnesses in the case, though their status could change to suspects depending on the outcome of the probe, officials said. "We will begin questionings of top decision makers of the companies (involved) ... this week to swiftly find the truth behind the so-called 'butler gate' and prevent the destroying of evidence," assistant special counsel Oh Jung-hee said in a regular press briefing. Oh said the investigation team also plans to seek arrest warrants for four key suspects connected to a stock manipulation case involving Sambu Construction Co. later in the day, including a former chairman and the current chairman, on charges of violating the Capital Markets Act. The case centers on allegations that company officials duped investors into buying the firm's shares in 2023 on false information that it would take part in reconstruction projects in war-torn Ukraine, then sold off their shares at inflated prices to pocket massive illegal profits. The former first lady is alleged to have played a role in the scheme.
